Ab0419 outcomes of the self-injection assessment questionnaire in rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis patients receiving gp2015 (etanercept biosimilar) in a real-world study: final results from compact study

Background COMPACT is an international, non-interventional cohort study evaluating the effectiveness, safety and quality of life in patients (pts) with rheumatoid arthritis (RA), axial-spondyloarthritis (axSpA) or psoriatic arthritis (PsA) treated with GP2015, an approved etanercept (ETN) biosimilar, in real-world conditions. Objectives To assess patient usage behaviour and feelings of self-administered injection with auto-injector device using the Self-Injection Assessment Questionnaire (SIAQ) in pts with RA, axSpA and PsA receiving GP2015. Methods Pts aged ≥18 years from Germany and UK who initiated treatment with GP2015 were enrolled in this study. The SIAQ, a questionnaire developed to assess overall pt experience with subcutaneous self-injection was used to assess the perceived self-confidence on self-injection, potential barriers as well as satisfaction with self-injection via device before the first self-injection (PRE module) and after dosing (POST module).[1] In COMPACT study, the POST module was assessed which comprised of 21 items grouped into 6 hypothetical domains: “feelings about injection”, “self-image”, “self-confidence”, “skin reaction” (injection-site reactions), “ease of use of self-injection device”, and “patient satisfaction”. Domain scores were rated on a 10-point scale, i.e., 0 (worst experience) to 10 (best experience). Data was analysed from the first collected SIAQ responses during the study and was summarised using descriptive statistics. The final SIAQ scores by domain in pts with RA, PsA and axSpA and by study group in pts with RA are reported here. Results A total of 458 pts from Germany (RA: 285, PsA: 79, axSpA: 94) and 273 pts from UK (RA: 174, PsA: 54, axSpA: 45) responded to the questionnaire. Overall, each domain showed high SIAQ scores which were consistent across all indications. The “self-image” and the “skin reaction” domains were scored highest (Figure 1). RA pts who had prior experience with biologic or non-ETN targeted medication (Group A + B) had mean scores mostly higher than or equal to those of biologic-naïve pts (Group C + D). RA pts who switched from iETN (reference ETN or biosimilar ETN other than GP2015) to GP2015 treatment (Group A) reported high SIAQ scores in all domains, which can be explained by good patient experience with the device (Table 1). Conclusion The SIAQ showed high acceptance of the auto-injector device in both countries where the survey was performed across all indications. Most RA pts were satisfied with auto-injector device usability after switching from iETN to GP2015, demonstrating no major concerns after switching. Reference [1] Keininger D, et al. Health Qual Life Outcomes. 2011,13;9:2 Acknowledgements: NIL. Disclosure of Interests Marc Schmalzing Speakers bureau: Novartis, AbbVie, AstraZeneca, Chugai/Roche, Janssen-Cilag, Gilead, Boehringer/Ingelheim, Mylan, Galapagos, EUSA-Pharma, Consultant of: Chugai/Roche, Hexal/Sandoz, Gilead, AbbVie, Janssen-Cilag, Boehringer/Ingelheim, onkowissen.de, EUSA-Pharma, Novartis, AstraZeneca, Amgen, medac, Lilly, Galapagos, UCB, Grant/research support from: Travel grants - Chugai/Roche, Boehringer/Ingelheim, Celgene, Medac, UCB, Mylan, Galapagos, Ayman Askari: None declared, Tom Sheeran Speakers bureau: Pfizer, UCB, Roche, Consultant of: Novartis, Pfizer, Grant/research support from: Novartis, UCB, Roche, Shrihari Jathanakodi Employee of: Sandoz Hexal AG, Charlotte Both Employee of: Sandoz Hexal AG, Herbert Kellner: None declared.